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Introduction: Therapeutic targeting of inhibitors of the immune response has reached
the clinical setting. Inhibitors of the novel receptor LAG3, which negatively regulates T-cell
activation, are under investigation. Here we explore the presence and prognostic role of
LAG3 in cancer.
Methods: A systematic search of electronic databases identified publications exploring
the effect of LAG3 on overall survival (OS) and (for early-stage cancers) disease-
free survival (DFS). Hazard ratios (HR) were pooled in a meta-analysis using generic
inverse-variance and random effect modeling. Subgroup analyses were conducted
based on disease site and tumor type.
Results: Fifteen studies met the inclusion criteria. LAG3 was associated with better
overall survival [HR 0.81, 95% confidence interval (CI) 0.66–0.99; P = 0.04], with
subgroup analysis showing no significant differences between disease-site subgroups.
The beneficial effect of LAG3 on OSwas of greater magnitude in early-stagemalignancies
(HR 0.73, 95% CI 0.60–0.88) than in the metastatic setting (HR 1.20, 95% CI 0.70–2.05),
but this difference was not statistically significant (subgroup difference p = 0.18). LAG3
did not have a significant association with DFS [HR 1.02, 95% confidence interval (CI)
0.77–1.37; P = 0.87], with subgroup analysis showing worse DFS in patients with
lymphoma and improved DFS in those with breast cancer.
Conclusions: High expression of LAG3 is associated with favorable overall survival in
several solid tumors. A trend toward an association in early-stage disease suggests the
importance of immune surveillance in this setting.
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INTRODUCTION
Inhibiting receptor downregulators of the immune response
has become an attractive therapeutic approach, with successful
results in some cancers (1). Inhibition of some of these
receptors, including cytotoxic T-lymphocyte-associated protein-
4 (CTLA-4) and programmed cell death-1 (PD-1) and its
ligand PD-L1, has been shown to have anti-tumoral effects
by inducing an effector response on CD8+ T cells (1–4).
Compounds of this family have been approved in different
indications, such as non-small cell lung (NSCLC), head and neck,
bladder, and triple-negative breast cancers (5–9). In some but
not all tumors, the presence of PD-L1-expression or markers
associated with genomic instability such as tumor mutational
burden or neo-antigen load predicts response to checkpoint
inhibitors (5, 10–12).
For immune checkpoint inhibitors to be active, tumors
must be in an inflamed or pre-activated state; so-called
“hot tumors” (13). In this context, the presence of tumor-
infiltrating lymphocytes (TILs) is necessary for adequate immune
response (14, 15). Other co-inhibitory receptors have been
described, including T-cell immunoglobulin and mucin-domain
containing-3 (TIM-3) or the lymphocyte-activation gene-3
(LAG3) (16, 17). LAG3 is a transmembrane protein with
structural homology to the CD4 co-receptor. It is found in
activated CD4+ T cells, T-regulator cell, Tr1 cells, activated
CD8+ T cells, natural killer cells, dendritic cells, B cells, and
exhausted effector T cells (17, 18). The ligands for LAG3
include MHC class II molecules, galectin-3, liver sinusoidal
endothelial cell lectin, and fibrinogen-like protein I (18, 19).
Although the precise molecular mechanisms remain elusive,
LAG3 negatively regulates the proliferation, activation, and
effector function of T cells. To date, it is regarded as one of
the multiple immune-checkpoint inhibitors that can promote
immune tolerance through T-cell dysfunction and exhaustion
(17, 18). Such negative effects seem to rely on the direct inhibition
of CD3-mediated T-cell proliferation, cytokine production, and
calcium flux (20). However, its suppressive effects are less
apparent than those elicited by PD-1 or CTLA-4 in preclinical
studies, suggesting the potential for a better safety profile (21,
22). Given its role as a negative regulator of T-cell activation,
strategies aiming to inhibit its action are currently in clinical
development (17, 23, 24). For both TIM-3 and LAG3, therapeutic
antibodies are in clinical development, mainly in combination
with inhibitors of PD-1 or PD-L1 (25).
The presence of TILs within the tumor is associated with
a favorable outcome, demonstrating that the existence of an
immune-activated state predicts an improved prognosis as
well as response to immunotherapy (15, 26). In addition, the
expression of PD-1 and PD-L1 is associated with a good
outcome irrespective of treatment with immune checkpoint
inhibitors, supporting the importance of the adaptive immune
response (27–29). In this article, we aim to explore the
frequency of expression and prognostic role of LAG3. We
hypothesized that the expression of LAG3 would be associated
with worse outcomes due to its inhibitory effects on the
immune response.
METHODS
Data Sources and Searches
This analysis was conducted following the Preferred Reporting
Items for Systematic Reviews and Meta-analyses (PRISMA)
guidelines. An electronic search of MEDLINE (host: Pubmed)
from 1946 to March 30th, 2019 was performed using the search
terms: “lymphocyte activation gene 3” or “LAG3” and “Cancer,”
limiting results to studies in humans. Citation lists of the
retrieved articles were screenedmanually to ensure the sensitivity
of the search strategy.
Study Selection
Eligibility criteria for studies included: (i) studies of humans
(adults and children); (ii) patients with hematological or solid
tumors; (iii) reporting of a hazard ratio (HR) for overall survival
(OS) and/or disease-free survival (DFS; defined as the length
of time from primary treatment of an early-stage cancer to
death or any signs or symptoms of recurrent cancer) or survival
curves allowing estimation of the HR for OS or DFS; (iv)
availability as a full-text publication; (v) clinical trials, cohort,
or case-control studies; and (vi) English language publication.
Case reports, conference abstracts, and letters to editors were
excluded. The titles identified by the initial search were
evaluated, and potentially relevant publications were retrieved
in full. Two authors (JFA and PP) reviewed the full articles
independently for eligibility. Disagreements were resolved
by consensus.
Data Extraction
The following data were collected from the included studies
using a predesigned abstraction form: name of first author,
year of publication, journal, number of patients included in
analysis, primary malignancy, protein expression, methods used
for the evaluation of LAG3, and cut-off used for defining LAG3
intensity. Data extraction was performed by one author (RS).
The outcome of interest was OS in patients both with and
without LAG3-expression as defined by the individual studies.
The HR for OS was extracted whenever available. In cases
where the HR was not reported, it was estimated from survival
curves for OS using the methods described by Parmar et al.
(30). We applied a hierarchal approach to the collection of
HRs, preferring those reported from multivariable analyses to
univariable HR, and preferring both over HRs estimated from
survival plots.
Data Synthesis and Statistical Analysis
The extracted data were pooled using RevMan 5.3 analysis
software (Cochrane Collaboration, Copenhagen, Denmark).
Estimates for HRs were pooled and weighted by generic inverse
variance and computed by random effect modeling. Statistical
heterogeneity was assessed using the Cochran’s Q and I2
statistics. Subgroup analyses were performed for different disease
sites. Differences between the subgroups were assessed using
methods described by Deeks et al. (31). Sensitivity analyses
were performed, excluding studies in pediatric tumors and
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when LAG3-expression was evaluated using ELISA rather than
immunohistochemistry (IHC) or next-generation sequencing
(NGS). NGS sub-analysis was done between genetic variants A/G
and G/G, with A/A as the referent group. A post-hoc exploratory
analysis was performed to evaluate associations between the
expression of LAG3 and other immunemarkers, including tumor
mutational burden (TMB) and neoantigen burden. All of the
statistical tests were two-sided, and statistical significance was
defined as p < 0.05. No correction was applied for multiple
statistical testing.
RESULTS
Fifteen retrospective studies comprising 6,306 patients were
identified (Figure 1) (32–46). The characteristics of the included
studies are listed in Table 1. LAG3 was reported as positive in
1,868 patients (31%). Fourteen studies explored the prognostic
influence of LAG3 in adults, and one study was performed
in a pediatric population. Two studies did not report OS
outcomes, and five studies did not report DFS. The eligible
studies explore outcomes in patients with breast, ovarian, gastric,
lymphoma, NSCLC, colorectal, and renal cancers as well as
pediatric neuroblastoma. Only two studies reported the use
of neoadjuvant therapy, which was based on taxane/platinum
combinations for breast cancer patients and 5-fluorouracil
± bevacizumab for colorectal cancer patients (32, 34). The
eligible studies either did not deliver neoadjuvant therapy
(n = 4) or excluded patients receiving pre-operative systemic
therapy (n = 7) (36, 38, 40–42, 44, 46). Only two patients
in the cohort of neuroblastoma were exposed to adjuvant,
IL-2-based, immunotherapy (37). As for the rest of the
studies, data on the treatment regimens was either not
reported or details were incomplete, thereby not allowing
additional investigation.
Overall Survival
Data for the association between LAG3 and OS were reported
in 13 studies. LAG3 was associated with better overall survival
[HR 0.81, 95% confidence interval (CI) 0.66–0.99; P = 0.04,
Figure 2A]. Heterogeneity was statistically significant (Cochran
Q P < 0.001, I2 = 64%). Subgroup analysis showed that there
were no significant differences between disease-site subgroups
(Subgroup difference P = 0.24, Figure 2B). There was no
significant difference between testing for LAG3 using IHC or
DNA extraction (HR 0.79, 95% CI 0.58–1.07 vs. HR 0.91, 95%
CI 0.73–1.14; subgroup difference P = 0.45). There was also
no significant difference between genetic variants A/G and G/G
relative to the A/A control group (subgroup difference P= 0.83).
The beneficial effect of LAG3 on OS was of greater magnitude
in early-stage malignancies (HR 0.73, 95% CI 0.60–0.88) than
in the metastatic setting (HR 1.20, 95% CI 0.70–2.05), but this
difference did not meet the statistical significance requirement
(subgroup difference p = 0.18). Subgroup analysis showed that
there was a greater magnitude of favorable prognosis with
LAG3 expression in terms of OS when HRs were extracted
rather than estimated (calculated HR 0.60, 95% CI 0.40–
0.91, extracted HR 0.92, 95% CI 0.75–1.12). This difference
FIGURE 1 | PRISMA of the study selection process for LAG3.
approached but did not reach statistical significance (p for
difference= 0.07).
Disease-Free Survival
Data for the association between LAG3 and disease-free survival
(DFS) were reported in 10 out of 15 studies that included early-
stage cancers. LAG3 did not exhibit a significant association with
DFS [HR 1.02, 95% confidence interval (CI) 0.77–1.37; P = 0.87,
Figure 3A]. Heterogeneity was statistically significant (Cochran
Q P< 0.001, I2 = 70%). There was an association with worse DFS
for lymphoma (HR 4.16, 95% CI 1.77–9.78, p = 0.001) and, to a
lesser extent, NSCLC (HR 1.48, 95% CI 0.98–2.23, Figure 3B).
Improved DFS was noted in the breast cancer group (HR 0.64,
95% CI 0.42–0.98). Excluding lymphoma and breast cancer, there
was no significant difference between the remaining tumors
(Subgroup difference P = 0.57), but heterogeneity remained
statistically significant (Cochran Q P = 0.006, I2 = 63%). There
was a modest and non-significant association between LAG3 and
improved DFS in early-stage malignancies (HR 0.82, 95% CI
0.62–1.08) compared to the metastatic setting (HR 0.91, 95% CI
0.64–1.31), but this difference did not meet statistical significance
requirements (subgroup difference p = 0.17). Again, subgroup
analysis showed that there was a borderline significant difference
in the prognostic value of LAG3 expression in terms of DFS
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TABLE 1 | Characteristics of included studies regarding LAG3.
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IHC, Immunohistochemistry; CLL, Chronic lymphocytic lymphoma; Ab, antibody; OS, Overall survival; RFS, Residual-free survival; NGS, Next-Generation Sequencing; Early, Early-stage
disease (Stage I–III); Metas., Metastatic disease (Stage IV).
based on whether HRs were extracted or estimated (calculated
HR 1.12, 95% CI 0.46–2.72, extracted HR 0.96, 95% CI 0.72–1.27,
p= 0.07).
Correlation of LAG3 With Other
Immunological Markers
The analysis of potential associations between LAG3 expression
in TILs and other biomarkers in our work was hindered by
the small number of studies providing combined data on
PD-1, PD-L1, CD8, TIM3, and TMB. In a cohort of breast
cancer patients, PD-L1, PD-1, and CD8 were positive in 53,
61, and 26% of LAG3+ TILs, respectively. In one study,
concurrent infiltration of LAG3+ and CD8+ TILs in ER-
breast cancer patients was associated with significantly longer
DFS (HR 0.49, 95% 0.32–0.74) (32). Of note, LAG3+/PD-
L1+ TILs have been identified in 15% of patients with triple-
negative breast cancer (45). In an NSCLC cohort, PD-L1
and PD-1 were expressed in 47 and 70% of LAG3+ TILs,
respectively. Up to 31% of NSCLC with LAG3+ TILs also
expressed PD-L1 and, of note, the group of tumors without
expression of either PD-L1- or LAG3- TILs showed longer
relapse-free survival (2.09 years) than the group with PD-L1+
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FIGURE 2 | Forest plots showing hazard ratios for overall survival: LAG3 overall (A) and by subgroups based on disease site (B). Hazard ratios for each study are
represented by squares: the size of the square represents the weight of the study in the meta-analysis; the horizontal line passing through the square represents the
95% confidence interval. All statistical tests were two-sided. The diamonds represent the estimated pooled effect. Test for overall effect based on z-test. All P-values
are two-sided. CI, confidence interval; OR, odds ratio. (A) LAG3 OS Overall. (B) LAG3 OS by disease site.
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FIGURE 3 | Forest plots showing hazard ratios for disease-free survival (DFS): LAG3 overall (A) and by subgroups based on disease site (B). Hazard ratios for each
study are represented by squares: the size of the square represents the weight of the study in the meta-analysis; the horizontal line passing through the square
represents the 95% confidence interval. All statistical tests were two-sided. The diamonds represent the estimated pooled effect. Test for overall effect based on
z-test. All P-values are two-sided. CI, confidence interval; OR, odds ratio. (A) LAG3 DFS overall. (B) LAG3 DFS by disease site.
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tumor cells and LAG3+ TILs (0.67 years) (46). Furthermore,
significant positive correlations have been reported in renal
cell carcinoma samples between LAG3 and CD8 and PD-1,
indicating not only the coexistence of biomarkers but
proportional variations (41). Finally, LAG3 and TIM3 appeared
to be co-expressed in up to 71% of cases of extranodal nasal
NK/T cell lymphoma (33). There were no data included on TMB
or neoantigen burden.
DISCUSSION
In the present article, we describe the frequency of expression
and prognostic value of LAG3 in several tumors. We find the
presence of LAG3 to be associated with better OS. In the included
studies, the effect was consistent in different tumor types. While,
on average, no effect on DFS was observed, there was significant
heterogeneity in effect between different disease sites. Of note
as an interesting finding is the marked association in early-
stage disease, which suggests an immunologic role in minimal
residual disease.
LAG3 is a co-inhibitory receptor that represses the effector
response of cytotoxic T cells (23, 24). In this context, several
therapies are currently in clinical development to inhibit its
activation, therefore facilitating an immune response (23).
Synergy has been reported with the combination of LAG3 and
PD-1 inhibition in murine models of melanoma, colorectal
cancer, liver cancer, and fibrosarcoma, achieving responses in
tumors largely resistant to single-agent immunotherapy (47).
Also, CTLA-4 inhibition has been found to elicit an increase in
the frequency of LAG3+ TILs in melanoma patients (48). These
findings, together with a better safety profile, underscore the
clinical interest of targeting LAG3 either alone or in combination
with other immune checkpoint inhibitors. It has been
demonstrated that concomitant treatment with LAG3 inhibitors
with anti-PD-1 or PD-L1 can produce an enhanced effect, and,
in this context, ongoing clinical studies are evaluating these
combinations (2).
No difference was found between the methods used for the
analysis of LAG3 expression or the different genetic variants
defining expression. This suggests the sensitivity of the observed
effect. Significant heterogeneity was observed among different
tumors, and thismay be a reflection of the heterogeneity observed
in the immune response and in the presence of TILs in the
different tumor types (49). This mirrors the discrepancy between
tumors in the objective responses observed when checkpoint
inhibitors are administered and the fact that response is not
associated consistently with the expression of PD1 or PD-L1 in
all tumor types (50).
An interesting finding is the association of LAG3 with a
better outcome in the early-stage disease. It is well-established
that the immune system plays a central role in avoiding
long-term relapses in early-stage tumors (51). Although this
effect is mediated by mechanisms that are not well-described,
the presence of an active immune state contributes to the
maintenance of cells in a quiescent state (51). In our study,
we unexpectedly identified a better outcome with LAG3 in
early-stage tumors. We are not aware of prior data reporting
this association.
An association between the expression of immune inhibitory
molecules such as PD-L1 and CTLA-4 and improved tumor
outcomes has been described previously (29, 52, 53). Such an
association seems paradoxical, since PD-L1, CTLA-4, and LAG3
elicit immunosuppressive responses and facilitate tumor escape.
However, the upregulation of these molecules may initiate a
negative feedback mechanism that creates an active immune
environment in an inflamed tumor, which leads to an improved
prognosis. Indeed, these markers usually overlap with CD8,
which reflects an active host immunity and has established
prognostic value (54). The expression of LAG3 was associated
significantly with expression of PD-L1 and CD8 in the only two
studies reporting such data (32, 41). More research is required to
confirm these results.
The early stages of disease have been linked to a more intact
host immunity and also to reduced tumor clonal heterogeneity.
There is growing evidence that neoantigen heterogeneity may
negatively influence immune surveillance and prognosis (55).
Whether early-stage cancers have amore intact immune response
due to a reduced pool of clonal neoantigens to target is a
hypothesis that warrants investigation.
Contrary to our findings, the expression of other immune
inhibitory receptors such as TIM3 has been associated with a
worse prognosis (56), although no analysis based on early- or
advanced-stage disease was performed. The results with LAG3
are more consistent with data observed with PD1 and PD-
L1, which demonstrates a clear favorable prognosis when these
markers are expressed (27–29).
The association between LAG3+ and other immunological
biomarkers could not be addressed systematically in our work
because of data scarcity. However, an association with biomarker
aggregation is suggested by some studies in breast, NSCLC,
and renal cancer patients (32, 41, 46). LAG3 and PD-1 have
been found to be co-expressed consistently on both CD4+
and CD8+ TILs in several murine cancer models. Additionally,
the co-inhibition of LAG3 and PD-1 elicits improved anti-
tumor CD8+ T-cell responses (47). Additional data are needed
to determine the impact on survival of aggregated biomarker
expression in TILs and/or tumor cells. Similarly, an association
has been described recently between tumors with LAG3+ TILs
and a higher TMB based on data from the Cancer Genome
Atlas (57). Unfortunately, none of the studies included in the
current analysis reported data on TMB. While heterogenous
and immature, this body of work suggests a functional interplay
between immune markers and TMB. This warrants further
research, especially regarding the potential for this interplay to
provide predictive or prognostic value.
This study has limitations. This is a retrospective analysis of
published articles. Therefore, it is susceptible to publication
bias and also relies on summary data, not individual
patient data. Furthermore, for some included studies (6
of 15), we estimated HR from survival plots, as it was not
reported in the individual articles. Subgroup analysis showed
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that there was no significant difference in the prognostic
value of LAG3 expression based on whether HRs were
extracted or estimated. Finally, only one cohort reported
data on hematologic malignancy and one on a pediatric
population, so additional data on the prognostic value of
LAG3 expression in hematological and pediatric malignancies
is warranted.
In conclusion, we report the prognostic role of LAG3 in
several tumors, suggesting that high expression is associated
with a favorable outcome, particularly in terms of OS. The
trend toward an association with outcome in early-stage disease
supports the importance of immune surveillance in the setting of
minimal residual disease.
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